Alkermes plc. Gain (Loss) on Sale of Equity Investments
Alkermes plc. (ALKS) reported Gain (Loss) on Sale of Equity Investments of $1.20 million for the 3-month period ending 2012-09-30, per its 10-Q filed 2013-01-31.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnSaleOfEquityInvestments · last filed 2013-01-31
- Alkermes plc. gain (loss) on sale of equity investments for the quarter ending 2012-09-30 was $1.20M.
| Period end | Gain (Loss) on Sale of Equity Investments 3 month |
|---|---|
| 2012-09-30 | $1.20M 10-Q · filed 2013-01-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |